Omalizumab for prevention of anaphylactic episodes in a patient with
severe mosquito allergy
- Elisa Meucci,
- Anna Radice,
- Fassio Filippo
, - Maria Loredana Chiara Iorno,
- Donatella Macchia
Elisa Meucci
Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro
Corresponding Author:elisa.meucci@uslcentro.toscana.it
Author ProfileAnna Radice
Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro
Author ProfileFassio Filippo
Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro
Author ProfileMaria Loredana Chiara Iorno
Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro
Author ProfileDonatella Macchia
Allergy and Clinical Immunology Unit, Ospedale San Giovanni di Dio, Azienda USL Toscana Centro
Author ProfileAbstract
Mosquito allergy can rarely give raise to severe clinical
manifestations.Here we describe the case of a patient suffering from
relapsing anaphylaxis after mosquito bites, who completely responded to
off label therapy with anti-IgE monoclonal antibody.This is the first
demonstration of the efficacy of omalizumab in such unusual
life-threatening allergy.06 Jun 2021Submitted to Clinical Case Reports 07 Jun 2021Submission Checks Completed
07 Jun 2021Assigned to Editor
28 Jun 2021Reviewer(s) Assigned
29 Jun 2021Review(s) Completed, Editorial Evaluation Pending
12 Jul 2021Editorial Decision: Revise Minor
30 Jul 20211st Revision Received
03 Aug 2021Submission Checks Completed
03 Aug 2021Assigned to Editor
03 Aug 2021Review(s) Completed, Editorial Evaluation Pending
15 Aug 2021Editorial Decision: Accept
